Drug intelligence / Profile preview

miR-345-5p mimic

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous, Intraperitoneal
01

Overview

miR-345-5p mimic is a synthetic RNA oligonucleotide designed to replicate the biological activity of the endogenous microRNA miR-345-5p. In preclinical research, it acts as a tumor suppressor in various cancers, including pancreatic cancer, lung adenocarcinoma, and papillary thyroid carcinoma, by downregulating specific oncogenic targets. In pancreatic cancer, it has been shown to attenuate metastasis by targeting the KLK7/E-Cad/β-Catenin/Rap1 axis. In other contexts, it targets RhoA, SETD7, and SOCS1. It is primarily used as a research tool to study gene regulation and potential therapeutic pathways in oncology and neuropsychiatric disorders like depression.

Other names
hsa-miR-345-5p mimichsa-miR345-5p mimichsa-miR 345-5p mimicmicroRNA-345-5p mimicmicroRNA345-5p mimicmicroRNA 345-5p mimic
02

Targets

SETD7 (SET domain containing lysine methyltransferase 7)Ras homolog family member A (mRNA)KLK7SOCS1 (Suppressor of cytokine signaling 1)

Beyond the preview

Go deeper on miR-345-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-345-5p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call